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Antimicrobial prescription patterns and ventilator associated pneumonia:
Findings from a 10-site prospective audit
Abstract
Objective: To examine anti-microbial prescribing practices associated with ventilator-associated
pneumonia from data gathered during an audit of practice and outcomes in intensive care units (ICUs) in
a previously published study. Results: The patient sample of 169 was 65% male with an average age of
59.7 years, a mean APACHE II score of 20.6, and a median ICU stay of 11 days. While ventilatorassociated pneumonia was identified using a specific 4-item checklist in 29 patients, agreement between
the checklist and independent physician diagnosis was only 17%. Sputum microbe culture reporting was
sparse. Approximately 75% of the sample was administered an antimicrobial (main indications: lung
infection [54%] and prophylaxis [11%]). No clinical justification was documented for 20% of prescriptions.
Piperacillin/tazobactam was most frequently prescribed (1/3rd of all antimicrobial prescriptions) with
about half of those for prophylaxis. Variations in prescribing practices were identified, including apparent
gaps in antimicrobial stewardship; particularly in relation to prescribing for prophylaxis and therapy deescalation. Sputum microbe culture reports for VAP did not appear to contribute to prescribing decisions
but physician suspicion of lung infection and empiric therapy rather than ventilator-associated pneumonia
criteria and guideline concordance.
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Abstract
Objective: To examine anti-microbial prescribing practices associated with ventilator-associated pneumonia from
data gathered during an audit of practice and outcomes in intensive care units (ICUs) in a previously published study.
Results: The patient sample of 169 was 65% male with an average age of 59.7 years, a mean APACHE II score of 20.6,
and a median ICU stay of 11 days. While ventilator-associated pneumonia was identified using a specific 4-item checklist in 29 patients, agreement between the checklist and independent physician diagnosis was only 17%. Sputum
microbe culture reporting was sparse. Approximately 75% of the sample was administered an antimicrobial (main
indications: lung infection [54%] and prophylaxis [11%]). No clinical justification was documented for 20% of prescriptions. Piperacillin/tazobactam was most frequently prescribed (1/3rd of all antimicrobial prescriptions) with about half
of those for prophylaxis. Variations in prescribing practices were identified, including apparent gaps in antimicrobial
stewardship; particularly in relation to prescribing for prophylaxis and therapy de-escalation. Sputum microbe culture
reports for VAP did not appear to contribute to prescribing decisions but physician suspicion of lung infection and
empiric therapy rather than ventilator-associated pneumonia criteria and guideline concordance.
Keywords: Antibiotics, Antimicrobial stewardship, Incidence, Mechanical ventilation, Prescription, Prevalence,
Surveillance, Ventilator-associated pneumonia
Introduction
Reducing hospital-acquired infection is an important
goal in improving quality of care and decreasing iatrogenic events for patients in hospital. Importantly,
consistent and systematic information about ventilatorassociated pneumonia-related (VAP) pathogens and
associated antimicrobial prescribing practices in Australasian intensive care units (ICUs) is scarce. There are
however some commonalities in pathogen types and
prescribing patterns available from the international literature. Reports from Europe and North America suggest
that microbes such as Acinetobacter baumannii, Staphylococcus aureus and members of the Enterobacteriaceae
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and Pseudomonas families are commonly associated with
VAP [1]. Patterns of infection may vary over time and
changes appear to be associated with antimicrobial use.
For example, one European centre noted increased Enterobacteriaceae isolation rates (suggested by the authors to
be related to antibiotic use), but unchanged S. aureus and
Pseudomonas aeruginosa rates over a 5 years period [1].
Internationally, antimicrobial prescription rates are
high in critical care, with prescriptions for VAP largely
compliant with practice guidelines [2, 3]. Nevertheless
some common areas have been identified for practice
improvement in antimicrobial stewardship, including the
use of culture-sensitive empiric therapy and appropriate
de-escalation of therapy [4].
Given this context of an increasing incidence if antimicrobial resistance and recognition of the negative impact
of hospital acquired infections, our aim was to develop a
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surveillance checklist for identification/screening of VAP
and conduct an audit in a sample of ICUs in Australia
and New Zealand to estimate the incidence of VAP. Audit
data collected included antimicrobials prescribed and
reports of microbial isolates in this cohort of mechanically ventilated patients.
The purpose of this brief research report is therefore
to present previously unpublished data on antimicrobial
prescription practices and offer our understanding of
these practices in a sample of ICUs.

Main text
Methods

A prospective 30-day audit on clinical surveillance of
VAP in 10 ICUs (9 in Australia, 1 in New Zealand) was
conducted; 7 were tertiary referral units [5]. A more
detailed report of the methods of the parent study was
previously published [6]. Briefly, invitations to participate
in the study were provided through mail distribution lists
to Australian and New Zealand Intensive Care Society
(ANZICS) members, with expressions of interest to participate received from medical directors of ICUs. Following institutional Review Board approval for each clinical
site ICU-based research coordinators collected audit data
for all patients: aged > 16 years; and mechanically ventilated (MV) for > 72 h.
Baseline data included age, gender, and diagnosis (at
ICU admission). At or after 72 h of MV, data were collected daily using a case report form including a specific VAP checklist (decreasing gas exchange, sputum
changes, chest X-ray infiltrates, inflammatory response;
Table 1), reports of sputum collection for laboratory
analysis (when ordered), microbes colonised (presence
of microbes in the absence of disease)/grown (fungus,
bacteria or virus) taken from microbiology laboratory
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reports, antimicrobial prescriptions for up to four medications each day, and independent ICU physician (intensivist) reports of VAP and infections, until ICU discharge.
Day 30 survival outcome while in hospital was also
recorded. A web-based database was used for data entry
at each site. Descriptive data analysis is reported, using
frequencies and proportions.
Results

The demographic and clinical characteristics of the final
sample of 169 patients are described in Table 2, along
with a summary of VAP identification using the checklist and independent physician diagnosis, sputum findings and antimicrobial prescribing activities. There was a
mean of eight data collection days per patient.
Of note, antimicrobial agents were prescribed in the
absence of abnormal sputum findings for 73% of the
data collection days. For VAP cases identified using the
screening checklist, antimicrobials were prescribed for
83% of patients, despite limited reporting of colonised
or infected sputum (from microbiology reports). Piperacillin/tazobactam comprised 32% of antimicrobial prescriptions. The main prophylaxis antimicrobials were
cefazolin (12 patients, mean 3 days), and piperacillin/
tazobactam (10 patients, mean 3 days); acyclovir was also
prescribed (6 patients, mean 4 days). No agents were prescribed simultaneously.
Discussion

Three key findings are noted from this microbialfocused report of the audit: (1) sputum collection for
microbiological culture and sensitivity testing were
rarely requested, and appeared irrelevant for prescribing practices in this sample; (2) antibiotics appeared
to be commonly prescribed for prophylaxis; and (3)

Table 1 Ventilator associated pneumonia (VAP) 4-item checklist
Item

Definition

1

PaO2/FiO2 ratioa ≤ 300 mmHg

Deterioration in gas exchange over last 24 h in the absence of cardiogenic pulmonary oedema or pulmonary
disease

2

Sputum changes

A change in sputum characteristics, increased volume, or colour changes (yellow or green)

3

Chest X-ray infiltrates

New localised or diffuse infiltrates on a single Chest X-ray (not explained by cardiogenic pulmonary oedema or
pulmonary disease)

4

Inflammatory response

≥ 1 of the following (in the absence of immunocompromise)

a ↑ Temperature

New and persistent (last 24 h) elevated body temperature ≥ 38 °C (or > 37.5 °C if concurrent anti-pyretic medication administration)

b WCC

White cell count ≤ 4 or ≥ 12 cells 109/L for 2 days

c ↑ Inflammation

Elevated serum inflammatory markers: C-reactive Protein (> 100 mg/L) or Procalcitonin (> 2.5 ng/L) for a single
blood test

Three days after a patient is commenced on mechanical ventilation, are any of the following clinical items present?
WCCwhite cell count
a

PaO2/FiO2 ratio: arterial oxygen tension divided by fraction of inspired oxygen
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Table 2 Summary of audit findings
Characteristic
Patient demographics (n = 169)
Age (median—years)

59

Sex—male (%)

65

APACHE II (mean)

20.6

Mechanical ventilation (median [IQR]—days)

7 [5–12]

Length of stay (median—days)
  ICU
  Hospital

11
30
n/patient days

Antimicrobial
prescribedb
n/patient
days

VAP identifieda
Screening checklist

29/40

24 (83%)/34

Independent physician diagnosis

29/67

27 (93%)/60

Sputum findings
Colonisation

31/41

36/41 (88%)

Infectionc

51/94

64/94 (68%)

  Screening checklist

13/13

  Independent physician diagnosis

9/10

Antimicrobial prescriptions

%

Antibiotic

90

Antifungal
Indication for prescription (%)
Clinically-diagnosed lung infection

54

Prophylaxis

11

Bloodstream infection
a

6
80

9

Predominantly different sets of patients; five patients were classified with VAP using both methods

b

All patients classified with VAP using both methods received antimicrobials

c

Most frequently identified microbes: ‘Other Gram negatives’ and candida; ‘Pseudomonas sp.’; ‘Coagulase-negative staphylococcus’

treating physicians appeared to diagnose VAP and
prescribe antimicrobials based on clinical assessment,
both independent of the clinical signs reflected in the
VAP checklist and any available microbial reports.
While reports of sputum microbe isolates in patients
classified with VAP in this cohort were sparse, a number of microbes associated with VAP were identified.
Pseudomonas, Haemophilus, Methicillin sensitive
Staphylococcus aureus (MSSA), Methicillin resistant
Staphylococcus aureus (MRSA) and Escherichia coli are
commonly reported in the literature [7]. Antimicrobial
prescriptions were appropriate when sputum isolates
were identified.
Prescribing practices may be influenced by different
reporting practices and language in microbiological
reporting. For example, laboratory reporting specieslevel identification and/or antibiotic sensitivities may

lead to increased antibiotic prescriptions. Also of note,
antimicrobial prescription rates were 20% higher for
patients with colonised sputum compared to infected
sputum. It is known that many clinicians consider ‘colonisation’ as the beginning of microbial infection; only
a few consider colonisation and infection as different
processes. It appears that physicians relied on their
clinical judgement when prescribing antimicrobials.
Pulmonary infection accounted for just over half of
all antimicrobial prescriptions in this sample; 10% lower
than international estimates of the prevalence of infection types in ICU (64%) [8]. Given the study design, we
were unable to examine physician considerations of factors known to affect treatment effectiveness (e.g. previous
antimicrobial exposure; antibiogram for each setting).
Considering local antibiograms is now highly recommended when prescribing antimicrobials for nosocomial
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pulmonary infections to reduce the incidence of resistant
organisms [9].
The rate of antimicrobials prescribed as an apparent
prophylaxis was high (11%), given that our inclusion criteria likely excluded the majority of patients treated in
ICU for postoperative care. The duration of treatment
and types of antimicrobials (i.e. cefazolin and piperacillin/tazobactam) prescribed for prophylaxis was of
concern, given that a single only antimicrobial dose is
recommended for the majority of surgeries. One possible explanation for this was the use of empiric therapy;
physicians suspected, but could not confirm, a respiratory infection; or were attempting to prevent pneumonia
within the setting of immunosuppression (we did not collect data about immune status).
Importantly, while one in 10 prescriptions for prophylaxis is reflective of prescribing practices in Australian hospitals, this is double the target of 5% set by the
national peak body [10]. This rate may however be
reflective of prescribing practices in ICU, where rates
are approximately twice those found in other hospital settings [10]. It would also appear that de-escalation
of antimicrobial therapy was not extensively practiced,
given the duration of broad spectrum antibiotic therapy.
Prescription rates in Australia are among the highest in
the developed World, so practices identified here may be
reflective of overall health care practice in the country
[10].
Antimicrobials were prescribed for more days for
patients with a physician-diagnosis of VAP (compared
to the VAP checklist). This is a logical finding, given that
once a physician diagnosed (and documented) the presence of pneumonia, specific treatment would follow.
Interestingly, the type of antimicrobial prescribed for
patients with possible VAP using the screening checklist
(e.g. Gram-negative antibiotics with anti-pseudomonal
activity) suggested that treatment was focused on a pulmonary infection.
Isolated sputum microbes were different for the two
methods of VAP ‘diagnosis’ or ‘identification’ (noting that
only five patients [17%] were classified using both methods). Given the small number of patients classified as
having VAP, potential reasons for this variation cannot be
elucidated; it is however unlikely that clinical differences
such as patient ICU admission diagnosis and severity of
illness were influencing factors [6].
This audit of 10 ICUs in Australia and New Zealand
identified variations in antimicrobial prescribing practice in the context of VAP. Ordering of sputum microbial
isolates was rare, and therefore the contribution of these
reports to prescribing decisions was not evident, given
the frequency of antimicrobial prescriptions for lung
infection. It therefore appears that prescribing decisions
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were based on clinician suspicion of an infective lung
process, and empiric therapy rather than the use of identified VAP criteria and guideline concordance. From an
antimicrobial stewardship perspective, opportunities
for reflections on and improvements in practice are evident, including reducing the prevalence of prescribing for
prophylaxis, and de-escalation of antimicrobial treatment
according to accepted practice guidelines and recent
expert recommendations [3].

Limitations
From a methodological perspective, the audit design
enabled sampling from multiple sites using a consistent, standardised data collection approach. Most study
ICUs were however large tertiary-referral units, potentially limiting the representativeness of this sample to
the broader ICU population, particularly for different
countries and health systems. A limitation of using independent assessors in data collection was that the realtime, decision-making processes of physicians during
their independent diagnosis of VAP and/or their antimicrobial prescribing practices remains unknown. Our
interpretations are therefore based on objective clinical
diagnostic and microbiological data collected during the
audit. We did not also collect data about the individual
ICU contexts, specifically their antimicrobial policies
(e.g. stewardship) and local antibiograms at the time data
were collected.
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